PFAS Health Screening Recommendations: What Doctors Advise After Exposure

If you have been exposed to PFAS through contaminated drinking water, military service, or occupational contact, knowing which health screenings to prioritize can help catch problems early. In 2022, the National Academies of Sciences, Engineering, and Medicine published detailed clinical guidance for healthcare providers treating PFAS-exposed patients. Here is what that guidance recommends — and why early detection matters.

The National Academies 2022 Clinical Framework

The National Academies' 2022 report, Guidance on PFAS Exposure, Testing, and Clinical Follow-Up, is the authoritative clinical reference for U.S. healthcare providers treating patients with potential PFAS exposure. It was developed by a multidisciplinary panel including epidemiologists, oncologists, endocrinologists, nephrologists, and environmental health physicians.

The framework organizes clinical recommendations around blood serum PFAS levels (in ng/mL of total measured PFAS), creating three tiers of follow-up intensity. Even if you have not been tested, the guidance also provides recommendations for patients with suspected significant exposure.

Tier 1: Total PFAS Below 7 ng/mL

Patients with total PFAS blood levels below 7 ng/mL — roughly the median for the general U.S. adult population — are advised to maintain routine healthcare and follow standard preventive care guidelines for their age and sex. The guidance recommends discussing PFAS exposure with the healthcare provider, minimizing ongoing exposure (switching water sources, filtering drinking water), and following standard dietary and lifestyle recommendations that may reduce health risks.

Even at this tier, the guidance recommends avoiding known sources of ongoing PFAS exposure: filtering drinking water with certified PFAS filters if your system has any detectable PFAS, avoiding PFAS-containing cookware, and reducing consumption of foods known to be high in PFAS (certain seafood and contaminated produce from affected agricultural areas).

Tier 2: Total PFAS 7–14 ng/mL

Patients in this range have PFAS levels above the general population median, suggesting more significant exposure than average. The National Academies recommends enhanced monitoring:

• Lipid panel (cholesterol): PFAS exposure is associated with elevated cholesterol (hypercholesterolemia). Annual or biennial lipid testing is advised, with appropriate follow-up if cholesterol is elevated.
• Thyroid function testing (TSH): PFAS disrupts thyroid hormone metabolism. Annual thyroid-stimulating hormone (TSH) testing screens for thyroid dysfunction before symptoms develop.
• Kidney function: Serum creatinine and estimated glomerular filtration rate (eGFR) to monitor kidney health. PFAS is associated with kidney cancer and may affect renal function.
• Blood pressure monitoring: PFAS exposure has been associated with hypertension. Blood pressure should be monitored at each clinical visit.
• Pregnancy and reproductive counseling: For patients who are pregnant or planning pregnancy, PFAS exposure is associated with pregnancy-induced hypertension and reduced birth weight. Discuss PFAS exposure with your OB/GYN.
• Immune function awareness: PFAS is associated with reduced vaccine efficacy and altered immune response. Ensure vaccination status is current and discuss any recurrent infections with your provider.

Tier 3: Total PFAS Above 14 ng/mL

Patients with PFAS blood levels above 14 ng/mL have substantially elevated body burden and are advised to pursue individualized clinical evaluation with a healthcare provider familiar with PFAS health effects. Recommendations at this tier include all Tier 2 monitoring plus:

• Cancer screening discussions: The guidance recommends individualized cancer risk assessment. For adults in this tier, early initiation of kidney cancer screening (imaging), testicular cancer awareness (self-examination and clinical exam for males), and age-appropriate cancer screening should be discussed with a physician.
• Hepatic function tests: Liver enzyme testing (ALT, AST) to screen for PFAS-associated liver disease, including non-alcoholic fatty liver disease (NAFLD).
• Uric acid levels: PFAS has been associated with elevated uric acid. Testing is recommended for symptomatic patients or those at risk for gout.
• Ulcerative colitis screening: For patients with gastrointestinal symptoms, PFAS exposure is a recognized risk factor for ulcerative colitis. Colonoscopy may be appropriate depending on symptom history and age.
• More frequent follow-up: Annual clinical follow-up with a provider familiar with PFAS health effects is recommended at this tier.

What to Tell Your Doctor

Many primary care physicians are not yet fully familiar with PFAS health effects or the National Academies clinical guidance. When discussing PFAS exposure with your doctor, you can bring the following information:

• The National Academies 2022 report is available free online at nap.nationalacademies.org. The executive summary and clinical guidance tables are the most relevant sections for primary care providers.
• The ATSDR's clinical PFAS page provides practitioner resources and educational materials specifically for healthcare providers.
• If your community has documented contamination, your state health department may have provider guidance or referral resources for PFAS-exposed patients.

You have the right to ask your doctor about PFAS-specific screening. If your doctor is unfamiliar with the guidance, you can politely share these resources and request the recommended tests.

Pediatric and Adolescent Considerations

Children and adolescents who grew up in PFAS-contaminated areas face unique risks. PFAS exposure in early life is associated with:

• Altered immune response and reduced vaccine efficacy
• Thyroid disruption during development
• Elevated cholesterol in childhood and adolescence
• Potential impact on puberty timing

The National Academies guidance includes pediatric-specific recommendations, particularly around cholesterol and thyroid monitoring. If your child grew up in a PFAS-contaminated area, discuss PFAS-specific screening with their pediatrician.

The Connection to Legal Claims

Routine health monitoring for PFAS-exposed individuals serves a dual purpose: early detection of health problems, and documentation that may be relevant to a legal claim. Medical records showing elevated PFAS blood levels followed by a PFAS-linked diagnosis create a documented timeline of exposure and injury. Gaps in medical records — periods where no testing was done — can make it harder to reconstruct this timeline later. Staying current with recommended screenings protects both your health and your legal options.